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Background: In metabolomics, thousands of substances can be detected in a single
assay. This capacity motivates the development of metabolomics testing, which is
currently a very promising option for improving laboratory diagnostics. However,
the simultaneous measurement of an enormous number of substances leads to
metabolomics data often representing concentrations only in conditional units,
while laboratory diagnostics generally require actual concentrations. To convert
metabolomics data to actual concentrations, calibration curves need to be generated
for each substance, and this process represents a significant challenge due to the
number of substances that are present in the metabolomics data. To overcome this
limitation, a label-free standardization algorithm for metabolomics data is required.
Results: It was discovered that blood plasma has a set of stable internal standards.
The appropriate usage of these newly discovered internal standards provides a
background for the label-free standardization of metabolomics data that underlies
the SantaOmics (Standardization algorithm for nonlinearly transformed arrays in Omics)
algorithm. In this study, using the knee point, it was shown that the metabolomics data
can be converted by SantaOmics into a standardized scale that can substitute actual
concentration measurements, thus making the metabolomics data directly comparable
with each other as well as with reference data presented in the same scale.
Conclusion: The developed algorithm sufficiently facilitates the usage of metabolomics
data in laboratory diagnostics.
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Background
In metabolomics-related methods, a large number of substances can be detected in a
single sample [1]. In the case of bodily fluid samples, this capacity provides great potential
for diagnostics [2, 3] that have been confirmed in numerous studies [1, 4]. However,
omics sciences, including metabolomics and proteomics, generally do not express the
concentrations of the detected substances in actual values. For example, in the mass spec-
trometric analysis of the blood plasma metabolome, the mass peak intensities reflect the
substance concentrations in the plasma. These mass peak intensities are expressed in
conditional units that are instrument-dependent: the type, model, settings, operating
state, etc. of the mass spectrometer directly fluctuate the peak intensity. Therefore, finger-
prints, patterns, barcodes, signatures, etc. [5], which have been successfully used in
numerous metabolomics-related ‘case–control’ studies, are unsuitable for laboratory
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diagnostics. In ‘case–control’ studies, the samples are typically analyzed under the same
conditions and compared with each other. This avoids the need to determine the actual
concentrations of the analyzed substances. However, to convert mass peak intensities to
actual concentrations, which is mandatory for medical purposes, calibration curves need
to be generated for each substance. This process represents a significant challenge due to
the number of substances detected in the metabolomics technologies and the limited
number of commercially available chemical standards required to build calibration curves.
The goal of this study was to overcome the aforementioned problem facing the devel-
opment of metabolomics tests. To this end, an algorithm that converts metabolomics
data of blood plasma into a standardized scale and directly allows comparison with
other data as well as with reference data was developed. This type of conversion allows
the measurement of thousands of substances in a single assay without using calibration
curves that may sufficiently facilitate the usage of metabolomics data in laboratory
diagnostics. This algorithm was named SantaOmics (Standardization algorithm for
nonlinearly transformed arrays in Omics).
Methods
Blood plasma sample preparation
Venous blood was collected from three volunteers (33-, 24-, and 23-year-old males)
into EDTA Vacutainer plasma tubes (BD, USA). Blood samples were processed accord-
ing to the manufacturer’s instructions. The resultant blood plasma was stored at −80 °C
until analysis. The analyzed samples were subjected to one freeze/thaw cycle. Plasma
(10 μL) was mixed with 10 μL of water (LiChrosolv; Merck KGaA, Darmstadt,
Germany) and 80 μL of methanol (Fluka, Munich, Germany). Next, after incubation at
room temperature for 15 min, the samples were centrifuged at 13,000 × g (MiniSpin
plus centrifuge; Eppendorf AG, Hamburg, Germany) for 10 min. Supernatants were
then transferred to clean plastic Eppendorf tubes, and fifty volumes of methanol con-
taining 0.1% formic acid (Fluka) was added to each tube. The resultant solution was
subjected to mass spectrometric analysis. The study design was approved by the rele-
vant ethical review committee.
To confirm that the volunteers did not have a sufficiently distorted blood plasma
composition, basic biochemical and blood parameters of these volunteers were measured
using routine automatic analyzers. Most of the parameter values fit within normal ranges
known in the field of clinical laboratory practice (see Additional file 1: Table S1).
Mass spectrometry analysis
Samples were analyzed by direct infusion mass spectrometry with a maXis hybrid
quadrupole time-of-flight mass spectrometer (Bruker Daltonics, Billerica, MA, USA), a
micrOTOF-Q hybrid quadrupole time-of-flight mass spectrometer (Bruker Daltonics,
Billerica, MA, USA), an OrbiTrap Elite mass spectrometer (Thermo Scientific, USA), a
Fourier transform ion cyclotron resonance mass spectrometer (Apex Ultra, Bruker
Daltonics, USA), and with an IFunnel Q-ToF mass spectrometer 6550 (Agilent Tech-
nologies, USA) equipped with an electrospray ion sources. Details are described in
the supplementary material [see Additional file 2]. The resultant metabolite ion
masses were pooled and processed using Matlab version R2010a (MathWorks, Natick,
MA, USA). This and all other calculations were performed using Matlab software.
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Mass spectra standardization by the SantaOmics algorithm
A fragment width of m/z 50 was selected as the start of the mass spectrum (i.e., at the edge
with the lowest m/z values). The mass spectrometric peaks located inside the fragment
were arranged according to their decreasing mass peak intensities. The curve approximat-
ing the intensity values was built using the fit function (here and below all mentioned
mathematical functions are from Matlab software) with the power equation (y = axb + c) as
the approximation type. The knee point of this curve was established by finding the first
and second derivatives (the source code is presented in the data repository). The knee point
determined the normalization value (see Fig. 1) for the m/z value in the middle of the se-
lected fragment. Iteratively, until the entire mass spectrum was processed, the fragment
was shifted by m/z 1 and all calculations were repeated. The calculated normalization
points were approximated by the curve (called the normalization curve) using the fit func-
tion (smoothing splaine as the approximation type). In order to obtain a mass spectrum in
a dimensionless instrument-independent scale, the intensity of each mass peak was divided
by the value of the normalization curve in the m/z point of the corresponding peak.
Test for knee point stability
The mass spectrometric data for the human blood plasma metabolome at m/z 225–275
was taken as an example of the omics data, and the mass peak intensities were fluctu-
ated (by iterations of 10) by random noise (by the use of the function normrnd) in
order to provide a peak intensity CV equal to 46%, the average CV for biological vari-
ation of the metabolites in blood plasma [6]. Simultaneously, the CV for the knee point
was measured with the aim to estimate its stability.
Fig 1 The concept for label-free standardization of metabolomics data. The actual concentrations of substances
in the blood plasma sample cover several orders of magnitude (a). When the substances are plotted according
to their decreasing peak intensity, their distribution obeys the power function (b). This function helps to find the
knee point for this distribution, which is defined by the assemblage of substances that makes it tolerant to
concentration fluctuations of separate substances. Moreover, the knee point is independent of the LOD of
the method, which may affect only the lower tail of the curve presented on the plot. While the substances
demonstrate a high concentration variation (e.g., average CV for biological variation of the blood plasma
metabolites is equal to 46% [6]), the knee point demonstrates a relatively low CV (7.7%). So, since the knee
point is stable, it may be used as a internal standard that is represented in all blood plasma samples. This
artwork was prepared as an example using actual mass spectrometric data for human blood plasma
metabolites in the m/z range of 225–275 (see details in Methods). R2, coefficient of determination for
the substances arranged according to their decreasing peak intensities and the power function
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Tests for the SantaOmics algorithm
The first test was related to the capacity of the SantaOmics algorithm to correct the
undesired variability in the mass spectra. The mass list from the mass spectrum of sam-
ple #3, obtained at a ‘low range’ mode of detection, was sufficiently distorted. The mass
peak intensities were multiplied (10×), linearly increased (from 1× in the low m/z area,
to 10× in the high m/z area), or nonlinearly distorted using the Gaussian function (in-
tensities in the low and high m/z areas were decreased (1/4), while the intensities in
the center of the mass spectrum were increased (4×)). So, all possible types of variabil-
ity were imitated by the selected types of distortions. The distorted mass lists were
standardized by the SantaOmics algorithm and then were compared with the standard-
ized nondistorted mass list of sample #3 by means of calculating the R2 value for linear
approximation of the peak intensities and the correlation coefficient (r).
The second test was related to the capacity of the SantaOmics algorithm to
standardize sufficiently divergent data obtained from the same instrument (intra-instru-
mental experiment). Such divergence may be a result of the variability, which appears
when different options are used for measurement. For this aim, the mass spectra ob-
tained by maXis in different ranges of detection (‘wide range’ and ‘high range’) were
standardized. The overlapping areas of these mass spectra were used to estimate their
identity (by calculating R2 and r).
The third test, which demonstrated the capacity of the algorithm to convert mass spectra
to the same scale, was performed using mass spectra from different mass spectrometers (in-
ter-instrumental experiment with maXis, micrOTOF-Q, OrbiTrap Elite, Apex Ultra, and
IFunnel Q-ToF mass spectrometers, thus providing data for mass spectrometers from the
same manufacturer and same design, as well as from different manufacturers and different
designs). The mass spectra were overlapped in order to visually compare them in terms of
the quality of scaling. Additionally, Spearman correlation coefficient determination and Pass-
ing Bablok analysis were performed to measure the slopes and intercepts in three independ-
ent experiments corresponding to blood plasma samples from three different volunteers.
Results
Development of the label-free data standardization algorithm for metabolomics data
In order to develop the label-free standardization algorithm, the characteristics of the
plasma samples required to provide a background for the stable internal standards were
determined. Generally, blood plasma samples contain substances with concentrations
covering several orders of magnitude (Fig. 1a). If the substances are plotted according
to their decreasing peak intensity (a measure of concentration), they will be arranged in
a smooth line, which can be easily approximated with the power function. The coeffi-
cient of determination (R2) value for this approximation will be approximately 1
(Fig. 1b). An easily detectable characteristic of this function is the knee point, which
corresponds to the maximum curvature of the line built by this function.
To confirm hypothesis that this knee point can be used as an internal standard, the sta-
bility of this point was tested. From the previously published data it was known that the
blood plasma metabolites demonstrate biological variation, with an average coefficient of
variation (CV) equal to 46% (Fig. 1a) [6]. In a model experiment, the metabolite intensities
were varied so that their CV was equal to 46%. Such a CV of the metabolites was reflected
in the CV of the knee point, which was equal to only 7.7%. Therefore, despite that the
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metabolites demonstrate a very high CV, it was observed that the knee point is relatively
stable. So, this simple model demonstrated that blood plasma samples have a stable in-
ternal standard. The knee point was characterized to be independent of the concentra-
tions of separate substances, due to its position being defined by the assemblage of
substances. In addition, the knee point was independent of the limit of detection (LOD)
of the measurement method (Fig. 1b). Thus, the appropriate usage of this newly discov-
ered internal standard provides a background for the label-free standardization of metabo-
lomics data that underlies the SantaOmics algorithm.
Application of SantaOmics to blood plasma metabolomics data
The mass spectrometric analysis of human plasma samples resulted in the detection
of ~17 thousands metabolite ions. Figure 2a illustrates a typical mass spectrum of
human blood plasma.
Fig. 2 Typical mass spectra of human blood plasma metabolites standardized according to the SantaOmics
algorithm. a The initial mass spectrum of human plasma metabolites. The mass spectrum was obtained
after the direct infusion of a blood plasma sample into an electrospray ion source of a hybrid quadrupole
time-of-flight mass spectrometer (maXis, Bruker Daltonics). b Detection of the normalization value for a particular
mass (m/z 225) in the mass spectrum. The substances from the selected range (m/z 225 ± 50) of the mass
spectrum are plotted according to their decreasing peak intensity. The place of maximum curvature of the
curve (knee point), which approximates the range of intensities, corresponds to the normalization value
(depicted by the arrow). c Maximum curvature detection by intensity derivative calculations. The derivative
maximum (depicted by the arrow) corresponds to the knee point, which indicates the normalization value
on the y-axis of plot B. d Normalization curve that was built by approximation of the normalization values
calculated over the entire range of the mass spectrum. e Standardized mass spectrum that was obtained
by dividing the peak intensities of the initial mass spectrum by the normalization curve
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Figure 2b and c shows the plots of substances arranged according to their de-
creasing mass peak intensities. From these plots, the knee point was determined to
be the point of maximum curvature of the function approximating these inten-
sities. A set of such knees was calculated for each part (with m/z 1 shift) of the
mass spectrum and was used to build a normalization curve for the entire mass
spectrum (Fig. 2d). In order to obtain a mass spectrum in the standardized form,
the intensity of each mass peak was divided by the value of the normalization
curve at the m/z point of the corresponding peak. Figure 2e depicts the standard-
ized mass spectrum, and the peak intensities are presented in an instrument-
independent scale.
Application of SantaOmics to distorted metabolomics data
To confirm the capacity of the SantaOmics algorithm to standardize the metabolomics
data, the algorithm was applied to crudely distorted mass spectra of the blood plasma
metabolome. Figure 3 shows the initial and linearly distorted as well as nonlinearly
distorted mass spectra before and after standardization by the SantaOmics algorithm.
Notably, such distortions cover all possible undesired variations in mass spectral data
that may be met in reality (e.g., signal drift, ion suppression of signal, different signal
strengths in different parts of the mass spectrum, etc.). The quality of standardization
was estimated by linear approximation for the corresponding peak intensities. R2 was
equal to 1, the slope was approximately 1, and the intercept was approximately zero
for all cases, allowing that the initial and distorted mass spectra after standardization
become equal and in the same scale. Therefore, any possible distortions presented in
a mass spectrum will be removed by the standardization procedure. So, metabolomics
data can be standardized and then compared with reference data as well as with diag-
nostic signatures expressed in the same scale, thus excluding the requirement of using
actual concentrations.
Application of SantaOmics to divergent intra-instrumental metabolomics data
The capacity of the algorithm to standardize divergent metabolomics data obtained
using different instrument measurement options was tested. The ‘wide’ and ‘high’
ranges of detection, which are characterized by sufficiently divergent measurement
options, were used for mass spectral analysis of the same sample. As a result, two
sufficiently different mass spectra were obtained, which were then standardized ac-
cording to the SantaOmics algorithm. The overlapping areas of the standardized
mass spectra were used to calculate the correlation coefficient and R2, which were
equal to 0.98 and 0.96, respectively (Fig. 4). This test demonstrated that even if suffi-
ciently divergent measurement options were used to obtain the metabolomics data,
these data still could be considered as qualitatively standardized scale after applying
the algorithm.
Application of SantaOmics to inter-instrumental metabolomics data
The most difficult examination for the SantaOmics algorithm was standardization
of the metabolomics data from different instruments. To this end, the algorithm
was applied to the mass spectra of the blood plasma metabolome, which were
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obtained by different mass spectrometers with different designs as well as options
used for mass measurement. Figure 5 visually confirms that the standardized mass
spectra are presented in the same scale. The objective equivalence of scales was
confirmed by inter-instrumental Passing Bablok analysis (Table 1) of the standard-
ized mass spectra, as shown by the values of the slopes (0.84–1.12) and intercepts,
as well as by the Spearman correlation coefficients (0.27–0.73). The same values for
hybrid quadrupole time-of-flight mass spectrometers, i.e., for mass spectrometers
with the same design, were expectedly better (slope, 0.88–1.09; Spearman correl-
ation coefficients, 0.67–0.73) than for the mass spectrometers with different designs.
These data related to the inter-instrumental reproducibility of the method are com-
parable with data reported for microarrays, i.e., for technology that measures actual
concentrations [7].
Fig. 3 The test results of the SantaOmics algorithm. The mass peaks were extensively distorted in different
ways, and the SantaOmics algorithm was applied to standardize the distorted mass spectra. The initial and
distorted by multiplication (10×) mass spectra before (a) and after (b) standardization. Initial and linearly
distorted (right corner is suppressed, left corner is powered) mass spectra before (c) and after (d)
standardization. Initial and nonlinearly distorted (right and left corner are suppressed, center of spectrum
powered) mass spectra before (e) and after (f) standardization. R2, coefficient of determination for linear
approximation of the data; the value equal to 1 confirmed that the SantaOmics algorithm is capable of
correcting extensive distortions in the mass spectra
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Fig. 4 Mass spectra of the same blood plasma sample obtained at different ranges of mass detection
before (a) and after (b) standardization, according to the SantaOmics algorithm. The overlapping area
of the standardized mass spectra (c) demonstrated the similarity in peak intensities. R2, coefficient of
determination for linear approximation of the data calculated for peak intensities; r, correlation coefficient
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Fig. 5 Mass spectra standardization by the SantaOmics algorithm in the inter-instrumental experiment. a-d
Overlapped mass spectra obtained by maXis and other mass spectrometers before standardization. e-h The
same mass spectra after standardization
Table 1 Averaged data for Passing Bablok analysis and Spearman correlation for mass spectra of
the same biosamples after normalization according to the SantaOmics algorithm
maXis Apex Ultra OrbiTrap Elite micrOTOF-Q IFunnel Q-ToF
maXis 0.46 ± 0.08 0.56 ± 0.09 0.70 ± 0.07 0.73 ± 0.04
Apex Ultra 1.01 ± 0.14
0.01 ± 0.01
– 0.68 ± 0.07 0.50 ± 0.07 0.27 ± 0.06




– 0.58 ± 0.12 0.34 ± 0.10






– 0.67 ± 0.10









All data are presented as the mean ± standard deviation for three independent experiments (i.e., for samples from three
volunteers). Individual data points are presented in Additional file 3: Tables S2-S10. The slopes and intercepts (just below
the slope values) for Passing Bablok analysis are presented in the lower left part of the table. The Spearman correlation
values are presented in the upper right part of the table
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Discussion
The SantaOmics algorithm, which standardizes metabolomics data and represents
them in a standardized scale as a valid substitution of actual concentration measure-
ments, was developed. The discovered stability inside the biosamples was the basis
for this algorithm. It was found that the point of maximum curvature (knee) of the
curve approximating the concentrations arranged in descending order for the sub-
stances presented in a blood plasma sample is stable. Variations in the concentra-
tions of highly abundant substances (corresponding to the high tail of the curve in
Fig. 1b) as well as of lowly abundant substances have no effect on the knee point.
The concentrations of any separate substances also do not have an effect on the knee
point because their position is defined by sets of substances. Because lowly abundant
substances do not have an effect on the knee point, its position generally is not
dependent on the LOD, thus making the algorithm applicable for different instru-
ments. The basis for such robustness of the knee point was demonstrated in a simple
simulation experiment (Fig. 1).
The characteristic nature of the knee point for blood plasma samples and its stability
have a fundamental basis. Any biological species is characterized by a genetically de-
fined molecular composition, which distinguishes this species from others and makes it
similar to other individuals of the same biological species. The stability of molecular
composition is supported by homeostasis. Namely, the molecular composition defines
the knee point because it is independent of the concentrations of separate substances.
Therefore, the knee point may be considered as a stable and ubiquitous internal stand-
ard, which is present in all blood plasma samples and can be found in metabolomics
data. This unique internal standard is independent of the type and strength of distor-
tion of the data and allows for label-free standardization of the metabolomics data. This
method was demonstrated on mass spectrometric metabolomics data. Dividing the
mass peak intensities by knee point values corresponding to m/z values of peaks con-
verts the entire mass spectrum into a standardized instrument-independent scale. Con-
sequently, the most applicable use of such standardization in medicine is the capacity
to compare mass spectra obtained in different laboratories and with reference data
presented using the same standardized scale for the same type of biosamples.
Calculation of the correlation and slope for the linear approximation is a common
way to estimate the reproducibility of inter-instrumental array data to which standard-
ized metabolomics data can be related. Previously, such information for metabolomics
data could not be obtained because SantaOmics is the first algorithm to make the
comparison of inter-instrumental metabolomics data reasonable. Thus, to estimate
the correlation and slope values, they can be compared with the same parameters for
microarrays. According to data from the MicroArray Quality Control consortium, the
comparison of inter-platform microarray data demonstrates a slope of 0.41–2.44 and a
correlation of 0.691–0.933 [7]. Therefore, metabolomics arrays, representing standardized
mass spectrometric data, demonstrate at least the same inter-platform reproducibility as
microarrays, which provide results in actual concentrations and some of which are already
accepted for clinical application. The main and most far-reaching conclusion from
these results is that metabolomics data already are beyond the limitation of usage only
in ‘case–control’ studies and that metabolomics data will soon become suitable for
clinical laboratory protocols.
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Conclusions
Using metabolomics, the measurement of almost all low molecular weight substances
present in bodily fluids in a single run will have many applications in health care
services. Label-free standardization of the test output simplifies data interpretation and
allows the biomedical test requirements to be met. The diverse metabolomics signa-
tures that already have been found, as well as will be found in the near future, cover a
broad range of tasks for which metabolomics testing can be developed, including dis-
ease diagnostics, risk assessment, estimation of biological parameters (e.g., biological
age, pregnancy, resistance to stress, fertility, potential longevity, etc.), and biochemical
high-throughput screening. All these tests can be performed by applying different
signatures to the standardized mass spectra of the blood plasma samples.
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